The global alpha emitter market size reached USD 581.6 million in 2023 and is expected to increase to around USD 1,488.02 million by 2033, notable at a CAGR of 9.90% from 2024 to 2033.
Key Takeaways
- North America contributed more than 44% of market share in 2023.
- Asia-Pacific is estimated to expand at the fastest CAGR between 2024 and 2033.
- By type of radionuclide, the actinium (Ac-225) segment has held the largest market share of 38% in 2023.
- By type of radionuclide, the radium (Ra-223) segment is anticipated to grow at a remarkable CAGR of 10.16% between 2024 and 2033.
- By application, the bone metastases segment generated over 36% of the market share in 2023.
- By application, the prostate cancer segment is expected to expand at the fastest CAGR over the projected period.
- By source, the natural sources segment generated over 54% of the market share in 2023.
- By source, the artificially produced sources segment is expected to expand at the fastest CAGR over the projected period.
The Alpha Emitter Market is a dynamic sector witnessing notable growth due to its applications in various industries. Alpha emitters, characterized by the emission of alpha particles, play a crucial role in medical, industrial, and research applications. The market’s evolution is marked by advancements in technology, expanding areas of application, and the increasing recognition of alpha emitters’ unique properties.
Get a Sample: https://www.precedenceresearch.com/sample/3690
Growth Factors:
Several factors contribute to the growth of the Alpha Emitter Market. The rising demand for alpha emitters in cancer therapy, particularly in targeted alpha-particle radiotherapy, is a significant growth driver. Additionally, advancements in nuclear medicine and the development of innovative alpha-emitting radiopharmaceuticals contribute to market expansion. The increasing prevalence of cancer and the continuous exploration of alpha emitters for new therapeutic interventions further propel market growth.
Alpha Emitter Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 9.90% |
| Global Market Size in 2023 | USD 581.6 Million |
| Global Market Size by 2033 | USD 1,488.02 Million |
| U.S. Market Size in 2023 | USD 179.13 Million |
| U.S. Market Size by 2033 | USD 466.72 Million |
| Base Year | 2023 |
| Forecast Period | 2024 To 2033 |
| Segments Covered | By Type of Radionuclide, By Application, By Source |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Metaverse in E-commerce Market Size Will be USD 936.28 Bn By 2033
Alpha Emitter Market Dynamics
Drivers:
The market is driven by technological advancements and the growing awareness of the benefits offered by alpha emitters. Alpha emitters, such as radium-223 and actinium-225, are increasingly utilized in cancer treatments, providing targeted and effective therapy with minimal damage to surrounding healthy tissues. Moreover, the expanding applications in industrial processes, including oil and gas exploration and quality control, drive the demand for alpha emitters, fostering market growth.
Restraints:
Despite the promising growth, the Alpha Emitter Market faces certain restraints. Regulatory challenges and safety concerns associated with the use of alpha emitters pose hurdles to market expansion. Strict regulations governing the handling and disposal of radioactive materials impact the market’s growth potential. Addressing these regulatory challenges and enhancing safety measures are critical for overcoming these restraints and ensuring sustained market development.
Opportunities:
The market presents significant opportunities driven by ongoing research and development activities. Continuous efforts to discover new alpha-emitting isotopes, coupled with their applications in targeted therapies and diagnostics, open avenues for market players. Additionally, collaborations between research institutions and industry stakeholders for the development of novel alpha-emitting radiopharmaceuticals create opportunities for market growth and diversification.
Competitive Landscape: The Alpha Emitter Market is characterized by intense competition among key players. Companies are focused on research and development to introduce innovative products, strengthen their market position, and gain a competitive edge. Strategic partnerships, mergers, and acquisitions are prevalent in the market, as companies aim to expand their product portfolios and geographical presence. The competitive landscape is shaped by the pursuit of technological advancements and the quest to meet the evolving demands of end-users across various industries.
Recent Developments
- In November 2022, NorthStar Medical Radioisotopes, a pharmaceutical company, and IBA Worldwide, a medical technology firm, unveiled a new agreement. NorthStar will acquire its third Rhodotron TT300 HE electron beam accelerator from IBA. This accelerator plays a crucial role in producing no-carrier added actinium-225 (Ac225), a vital therapeutic radioisotope facing limited supply and lacking commercial-scale production technology.
- In January 2022, biotechnology companies RadioMedix and Orano Med announced the commencement of a Phase II clinical trial for AlphaMedix. The trial, initiated on December 21, 2021, assesses the safety and efficacy of 212Pb-DOTAMTATE (AlphaMedix) in Peptide Receptor Radionuclide Therapy (PRRT) for patients with somatostatin receptor-expressing neuroendocrine tumors (NET) who are new to treatment.
- In June 2022, medical technology company Alpha Tau Medical Ltd. received approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE) application. This green light allows the initiation of a multi-center pivotal study using Alpha DaRT for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC).
Alpha Emitter Market Companies
- Alpha Tau Medical Ltd.
- NorthStar Medical Radioisotopes
- IBA Worldwide
- RadioMedix
- Orano Med
- Bayer AG
- Novartis International AG
- Actinium Pharmaceuticals, Inc.
- Fusion Pharmaceuticals Inc.
- Eckert & Ziegler
- Telix Pharmaceuticals Limited
- Curium Pharma
- AAA (Advanced Accelerator Applications)
- Isotopen Technologien München AG (ITM)
- Nordion (Canada) Inc.
Segments Covered in the Report
By Type of Radionuclide
- Radium (Ra-223)
- Actinium (Ac-225)
- Lead (Pb-212)
- Astatine-211
- Bismuth-213
- Others
By Application
- Bone Metastases
- Prostate Cancer
- Neuroendocrine Tumors
- Ovarian Cancer
- Others
By Source
- Natural Sources (Uranium-238, Radium-226)
- Artificially Produced Sources (Plutonium, Americium, Curium, Californium)
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Alpha Emitter Market
5.1. COVID-19 Landscape: Alpha Emitter Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Alpha Emitter Market, By Type of Radionuclide
8.1. Alpha Emitter Market, by Type of Radionuclide, 2024-2033
8.1.1 Radium (Ra-223)
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Actinium (Ac-225)
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Lead (Pb-212)
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Astatine-211
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Bismuth-213
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Alpha Emitter Market, By Application
9.1. Alpha Emitter Market, by Application, 2024-2033
9.1.1. Bone Metastases
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Prostate Cancer
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Neuroendocrine Tumors
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Ovarian Cancer
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Alpha Emitter Market, By Source
10.1. Alpha Emitter Market, by Source, 2024-2033
10.1.1. Natural Sources (Uranium-238, Radium-226)
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Artificially Produced Sources (Plutonium, Americium, Curium, Californium)
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Alpha Emitter Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.1.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Forecast, by Source (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Source (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Source (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Source (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Source (2021-2033)
Chapter 12. Company Profiles
12.1. Alpha Tau Medical Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. NorthStar Medical Radioisotopes
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. IBA Worldwide
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. RadioMedix
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Orano Med
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bayer AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis International AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Actinium Pharmaceuticals, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Fusion Pharmaceuticals Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Eckert & Ziegler
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
Blog: https://www.dailytechbulletin.com/
Blog: https://www.autoindustrybulletin.com/
